Wednesday, July 8, 2026

Patent intelligence · US

US 11001820

Delivery of therapeutic agents by a collagen binding protein

granted A61KA61K2039/505A61K2039/6031A61K2800/57
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 15
Applicant portfolio 72
Patent details — US 11001820
Jurisdiction
US
Status
granted
Grant date
May 11, 2021
Expiration
May 6, 2041
Claims
17
CPC classes
A61K, A61K2039/505, A61K2039/6031, A61K2800/57
View on Google Patents ↗

Quick answer

US 11001820 (Delivery of therapeutic agents by a collagen binding protein) is held by Montefiore Medical Center. Status: granted. Granted May 11, 2021. Expires May 6, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
17
CPC classes
A61K, A61K2039/505, A61K2039/6031, A61K2800/57, A61K38/00, A61K38/179

More from Montefiore Medical Center

Related pharmaceutical patents in our USPTO index.

  1. US 12391663

    Isoindolinone compounds

    Monte Rosa Therapeutics AG · Expires Aug 14, 2045

    granted
  2. US 12378199

    Rigidified pentadentate chelating agents useful for the [Al18F]2+ labelling of biomolecules

    UNIVERSITÀ DEGLI STUDI DEL PIEMONTE ORIENTALE “A. AVOGADRO” · Expires Jul 31, 2045

    granted
  3. US 12280029

    Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators

    INSTITUT PASTEUR DE MONTEVIDEO · Expires Apr 17, 2045

    granted
  4. US 12263143

    Ionic channel modulation as a method for treating tumors through inflammasome activation

    INSTITUT PASTEUR DE MONTEVIDEO · Expires Mar 27, 2045

    granted
  5. US 12257247

    Targeted degradation of VAV1

    Monte Rosa Therapeutics AG · Expires Mar 20, 2045

    granted
  6. US 12214218

    Perfusion modulated tumor dose sculpting with single dose radiotherapy

    FUNDAçÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD · Expires Jan 30, 2045

    granted
  7. US 12070628

    Low energy immune priming for treating cancer and metastasis

    Montefiore Medical Center · Expires Aug 22, 2044

    granted
  8. US 12011619

    Low intensity focused ultrasound for treating cancer and metastasis

    Montefiore Medical Center · Expires Jun 13, 2044

    granted

Frequently asked questions

What is US patent 11001820?

US 11001820 (Delivery of therapeutic agents by a collagen binding protein) is held by Montefiore Medical Center. Status: granted. Granted May 11, 2021. Expires May 6, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11001820?

Montefiore Medical Center is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 72 pharmaceutical patents for this assignee.

When does US 11001820 expire?

Our index shows an expiration date of May 6, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.